search
Back to results

DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH (TBENOSE) (TBENOSE)

Primary Purpose

Tuberculosis, Pulmonary, HIV Seropositivity

Status
Completed
Phase
Not Applicable
Locations
Cameroon
Study Type
Interventional
Intervention
Tor Vergata Electronic Nose (TV eNose)
Survey & Physical Exam
TB LAMP test
Sputum Samples
Chest X-Ray
Follow Up 5 days after beginning of Tx.
Follow Up & 15 days after beginning of Tx.
Follow Up & 30 days after beginning of Tx.
Sponsored by
University of Rome Tor Vergata
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Tuberculosis, Pulmonary focused on measuring Tuberculosis, Breath test, Volatile Organic Compounds (VOCs)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Accept to participate in the study through a signed informed consent approved by the Ethical Committee (CEI of Douala - Cameroon)
  • Suspected of having TB on clinical base (4SS + or other clinical suggestions) with HIV+/- status
  • Healthy control patient
  • Able to produce exhaled air samples
  • Able to produce sputum samples for TB LAMP test

Exclusion Criteria:

  • Unable to breath normally for 2 minutes due to respiratory illness
  • By discretion of the research team.

Sites / Locations

  • Centre des Maladies Respiratoire

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Pulmonary TB

Non Pulmonary TB

Arm Description

This arm will enroll 80-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with pulmonary TB proved by TB LAMP test. Interventions: They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, Physical Exam,and HIV status. Other interventions: Sputum samples for Ziehl Neelsen smear or Culture in L-J or GeneXpert MTB/RIF; Chest X-ray Follow Up 5 days after beginning of Tx Follow Up 15 days after beginning of Tx Follow Up 30 days after beginning of Tx

This arm will enroll 50-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with Negative pulmonary TB status proved by TB LAMP test. These Negative TB patients can be healthy controls or TB suspects. Interventions: They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, and HIV status. Other interventions: Sputum samples for Ziehl Neelsen smear or Culture in L-J GeneXpert MTB/RIF; Chest X-ray.

Outcomes

Primary Outcome Measures

Diagnostic Accuracy value of the TV eNose signal value to differentiate patients with Pulmonary TB to control participants
Sensitivity, Specificity and Predictive Values; calculated with an Receiver Operating Characteristic (ROC) curve based on the pattern recognition model from dataset measured by the TV eNose.The classification of the signal is generated with a complex pattern recognition software, using the frequency shift in Hertz (Hz), generated by each of the 12 sensors.
Accuracy value of the diagnostic between Pulmonary TB, Pulmonary TB+ HIV patients and control patients with the TV eNose
Sensitivity, Specificity and Predictive Values; calculated with an Receiver Operating Characteristic (ROC) curve based on the pattern recognition model from dataset measured by the TV eNose. The classification of the signal is generated with a complex pattern recognition software, using the frequency shift in Hertz (Hz), generated by each of the 12 sensors.

Secondary Outcome Measures

Average Days needed to observed a negative result with the device after initiation of treatment.
Get an evolutive model of the VOC pattern of the frequency from each patient under treatment. Characterize VOC pattern of Pulmonary TB with and without treatment

Full Information

First Posted
December 4, 2020
Last Updated
December 7, 2021
Sponsor
University of Rome Tor Vergata
search

1. Study Identification

Unique Protocol Identification Number
NCT04682990
Brief Title
DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH (TBENOSE)
Acronym
TBENOSE
Official Title
DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH TEST Center: Douala - CAMEROON
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
January 5, 2021 (Actual)
Primary Completion Date
December 5, 2021 (Actual)
Study Completion Date
December 5, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Rome Tor Vergata

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Tuberculosis (TB) is one of the top 10 causes of death in the world. More than 95% of TB deaths are in middle- and middle-income countries. Low incomes and long-term diagnosis promote this persistence. In 2017, Cameroon was the 3rd in the top of 20 countries with the highest estimated numbers of incident TB cases among people living with HIV, based on the severity of their TB burden. World Health Organization (WHO) encourages the introduction of rapid, non-invasive and cheaper screening tests. In this scope, this study proposes the collection of exhaled breath samples and their analysis through the electronic nose made in Tor Vergata University (TV eNose) to diagnose TB and TB-HIV on their participants.
Detailed Description
It is a 12 -month dynamic, open, descriptive and analytical type case-control study in adults. The present study intends to recruit , all the Pulmonary TB suspects and case notified by TB Loop-mediated isothermal Amplification(LAMP), sputum culture or GeneXpert Mycobacterium Tuberculosis/Rifampicin (MTB/RIF) Assay, Pulmonary TB+HIV patients, healthy control patients, HIV patients without TB. Each patient will undergo at least two tests: the Breath Test Measurement and the TB LAMP. The TB LAMP will be used like the reference test for positive TB cases. The enrolment phase of the participants will take 12 months. After this period, additional 6 months will be dedicated to the data analysis and dissemination of results. Each patient meeting the inclusion criteria will be asked to join the study. Detailed information will be provided him/her. In case of acceptance the participants will undergo further sampling: breath test measurement. All data will be collected ensuring anonymity and privacy. Standard protocols used in the center will not be changed by the research, but each patient will be asked to provide 1 additional sample (exhaled breath in the bag sampler). Each study participant will be properly informed, and a consent form will be signed. Preparation to participate: It will be required to patients to avoid drinking, eating, smoking, or brushing their teeth 2 hours before the breath test. Sampling collection: In order to collect breath samples, two bags will be used, one for collecting airways breath (about 0.5 liter volume) and one for alveolar exhaled air (3 liters). It is asked to the patient after putting a clip nose, to inspire with the mouth and to deeply breath inside the bags through an antibacterial filter connected to the sampling apparatus. At the end, the second bag (volume of 3 liters) contains the alveolar portion of breath that will be analyzed by the TV eNose. During the measurement, the TV eNose will be connected to the computer, to read and store the Volatile Organic Compounds (VOCs) pattern from breath given by the sensor array. Other data are collected: clinical symptoms, TB LAMP results, and results of others test if available: chest X-ray, smear microscopic, sputum culture and GeneXpert MTB/RIF Assay examinations. All personal data and results of the patients will be collected in a specific sheet elaborated by the partners (University di Roma Tor Vergata). It will be an Excel database and it will be store in the study site. All data collected will be anonymous.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, Pulmonary, HIV Seropositivity
Keywords
Tuberculosis, Breath test, Volatile Organic Compounds (VOCs)

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
Positive TB patients (Arm 1) and Negative TB patients (Arm 2 ). All the patients can be HIV positive or not .
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
130 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pulmonary TB
Arm Type
Experimental
Arm Description
This arm will enroll 80-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with pulmonary TB proved by TB LAMP test. Interventions: They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, Physical Exam,and HIV status. Other interventions: Sputum samples for Ziehl Neelsen smear or Culture in L-J or GeneXpert MTB/RIF; Chest X-ray Follow Up 5 days after beginning of Tx Follow Up 15 days after beginning of Tx Follow Up 30 days after beginning of Tx
Arm Title
Non Pulmonary TB
Arm Type
Active Comparator
Arm Description
This arm will enroll 50-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with Negative pulmonary TB status proved by TB LAMP test. These Negative TB patients can be healthy controls or TB suspects. Interventions: They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, and HIV status. Other interventions: Sputum samples for Ziehl Neelsen smear or Culture in L-J GeneXpert MTB/RIF; Chest X-ray.
Intervention Type
Device
Intervention Name(s)
Tor Vergata Electronic Nose (TV eNose)
Intervention Description
Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
Intervention Type
Other
Intervention Name(s)
Survey & Physical Exam
Intervention Description
Perform a oriented survey for risk factors, symptoms and a complete physical exam.
Intervention Type
Diagnostic Test
Intervention Name(s)
TB LAMP test
Intervention Description
Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
Intervention Type
Other
Intervention Name(s)
Sputum Samples
Intervention Description
Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
Intervention Type
Other
Intervention Name(s)
Chest X-Ray
Intervention Description
Perform anteroposterior chest X-ray (if required by the medical staff)
Intervention Type
Other
Intervention Name(s)
Follow Up 5 days after beginning of Tx.
Intervention Description
Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Intervention Type
Other
Intervention Name(s)
Follow Up & 15 days after beginning of Tx.
Intervention Description
Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Intervention Type
Other
Intervention Name(s)
Follow Up & 30 days after beginning of Tx.
Intervention Description
Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Primary Outcome Measure Information:
Title
Diagnostic Accuracy value of the TV eNose signal value to differentiate patients with Pulmonary TB to control participants
Description
Sensitivity, Specificity and Predictive Values; calculated with an Receiver Operating Characteristic (ROC) curve based on the pattern recognition model from dataset measured by the TV eNose.The classification of the signal is generated with a complex pattern recognition software, using the frequency shift in Hertz (Hz), generated by each of the 12 sensors.
Time Frame
6 months
Title
Accuracy value of the diagnostic between Pulmonary TB, Pulmonary TB+ HIV patients and control patients with the TV eNose
Description
Sensitivity, Specificity and Predictive Values; calculated with an Receiver Operating Characteristic (ROC) curve based on the pattern recognition model from dataset measured by the TV eNose. The classification of the signal is generated with a complex pattern recognition software, using the frequency shift in Hertz (Hz), generated by each of the 12 sensors.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Average Days needed to observed a negative result with the device after initiation of treatment.
Description
Get an evolutive model of the VOC pattern of the frequency from each patient under treatment. Characterize VOC pattern of Pulmonary TB with and without treatment
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Accept to participate in the study through a signed informed consent approved by the Ethical Committee (CEI of Douala - Cameroon) Suspected of having TB on clinical base (4SS + or other clinical suggestions) with HIV+/- status Healthy control patient Able to produce exhaled air samples Able to produce sputum samples for TB LAMP test Exclusion Criteria: Unable to breath normally for 2 minutes due to respiratory illness By discretion of the research team.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leonardo Palombi, Professor
Organizational Affiliation
University of Rome Tor Vergata
Official's Role
Study Director
Facility Information:
Facility Name
Centre des Maladies Respiratoire
City
Douala
State/Province
Littoral
Country
Cameroon

12. IPD Sharing Statement

Learn more about this trial

DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH (TBENOSE)

We'll reach out to this number within 24 hrs